Esperion (NASDAQ: ESPR) CFO sells shares to pay taxes on vested RSUs

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. Chief Financial Officer Benjamin Halladay reported an open-market sale of 10,773 shares of common stock at $3.155 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units. After this transaction, Halladay directly holds 702,829 shares, indicating he retains a substantial equity position in the company.

Insider Trade Summary

Net Seller: 10,773 shares ($33,989)

Net Sell 1 txn

Insider Halladay Benjamin

Role Chief Financial Officer

Sold 10,773 shs ($34K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,773	$3.155	$34K

Holdings After Transaction: Common Stock — 702,829 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 10,773 shares Sale price: $3.155 per share Shares owned after transaction: 702,829 shares

3 metrics

Shares sold 10,773 shares Open-market sale on 2026-06-17

Sale price $3.155 per share Price for common stock sold

Shares owned after transaction 702,829 shares Direct holdings after sale

Key Terms

restricted stock units, open-market sale, Chief Financial Officer

3 terms

restricted stock units financial

"tax obligation on vested shares of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Chief Financial Officer financial

"officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S		10,773(1)	D	$3.155	702,829	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Esperion Therapeutics (ESPR) report for its CFO?

Esperion Therapeutics reported that CFO Benjamin Halladay sold 10,773 shares of common stock. The shares were sold at $3.155 each to cover tax obligations related to vested restricted stock units, according to the footnote in the Form 4 filing.

Why did Esperion Therapeutics CFO Benjamin Halladay sell ESPR shares?

The filing states Halladay sold the shares to satisfy tax obligations on vested restricted stock units. Such tax-related sales are typically mechanical and linked to compensation events rather than discretionary portfolio decisions by the executive.

How many Esperion Therapeutics shares does the CFO hold after the reported sale?

After the reported sale, CFO Benjamin Halladay directly holds 702,829 shares of Esperion Therapeutics common stock. This indicates he continues to maintain a sizable equity stake in the company following the tax-related transaction described in the Form 4.

At what price were the Esperion Therapeutics shares sold in the CFO’s Form 4?

The reported transaction shows 10,773 shares of Esperion Therapeutics common stock sold at a price of $3.155 per share. This price reflects the execution level for the tax-related sale tied to vested restricted stock units.

Is the Esperion CFO’s June 2026 Form 4 transaction a routine tax sale?

The footnote explains the shares were sold to satisfy tax obligations on vested restricted stock units. This language indicates the transaction is tied to compensation-related tax withholding rather than a discretionary open-market sale for portfolio or valuation reasons.